System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Isabelle Desmoulins is an expert in Oncology at Centre Georges François Leclerc (France). As of October 2026, ScienceLeadR ranks Isabelle Desmoulins in the top 1% of experts worldwide for Breast Neoplasms and Breast Diseases. Isabelle Desmoulins has authored 175 publications, the most recent in 2026, and is an investigator in 27 clinical trials, 15 of them ongoing. SLR score: 820 (community average: 125). How the SLR is computed.

LeadR Profile

Isabelle Desmoulins Centre Georges François Leclerc France
820 ScienceLeadR Reputation 820

Unlock

Register Login
Network Map

Oncology

Subspecialties: Biochemistry - Radiotherapy - Dermatology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2012 - 2026
Source: PubMed

Centre Georges François Leclerc

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 175

Citations

Citations: 3 030 1st author: 3 Last author: 2 Unique author: 0

Main journals

Ann Oncol 22
Cancer Res 21
Eur J Cancer 17
J Clin Oncol 16
Breast 8

Best Journals

Ann Oncol 15
J Clin Oncol 10
N Engl J Med 2

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER +HER2 - breast cancer: a randomized phase 2 trial.
PMID 42350643 — radiotherapy, breast neoplasms, molecular biology, cold temperature, neoplasms, drug therapy, breast, therapeutics, tumor microenvironment, chemotherapy		Nat Med Top journal20264
Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer.
PMID 42229584 — breast neoplasms, neoplasms, drug therapy, hormones, breast, therapeutics, tamoxifen, chemotherapy		Ann Oncol Top journal20260
Characteristics and outcomes of patients with HER2-negative metastatic breast cancers with low expression of estrogen and progesterone receptors in the multicenter ESME cohort.
PMID 42160910 — estrogens, breast neoplasms, neoplasms, breast, therapeutics, receptors, progesterone, progesterone		Breast20260
Natural history and treatment sensitivity of alveolar soft part sarcoma: A national multicenter analysis from the French sarcoma group.
PMID 41719753 — natural history, drug therapy, immunotherapy, sarcoma, neoplasm metastasis, diagnosis, sarcoma, alveolar soft part, therapeutics, history, chemotherapy		Eur J Cancer20260
BRCA1/2, PALB2 mutations and first-line CDK4/6 inhibitor efficacy in HR+ metastatic breast cancer.
PMID 41713165 — breast neoplasms, neoplasms, breast, therapeutics, genes, brca1, mutation		Breast20260

Clinical Studies 27

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 6

By phase:

Phase 2 12
Phase 3 9
N/A 6

By status:

Recruiting 12
Completed 8
Active not recruiting 6
Unknown 1

By type:

Interventional 25
Observational 2

By Monocentric/Multicentric:

monocentric 4
multicentric2to4 2
multicentric5to9 3
multicentricup10 18

Main Topics

Ongoing Clinical Trials

15 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
INTER EWING 1 International Clinical Research Programme to Improve Outcomes in Newly Diagnosed Ewing Sarcoma Trial 1
2024-511989-36-00 — radiotherapy, sarcoma, ewing, biomedical research, drug therapy, sarcoma, research, chemotherapy		Phase 3Recruiting2025
Interest of post operative chemotherapy in patients with localized uterine leiomyosarcoma suspected to have a high risk of relapse based on a biologic test performed on the tumor
2023-506350-21-00 — leiomyosarcoma, neoplasms, classification, drug therapy, chemotherapy, adjuvant, chemotherapy		Phase 2Recruiting2025
Evaluating a Personalized Treatment Strategy for Young Women with Early Breast Cancer
2024-519655-28-00 — lymph nodes, breast neoplasms, neoplasms, multiple chronic conditions, neoplasm micrometastasis, lymph, breast, therapeutics, women		Phase 3Recruiting2026
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Phesgo (pertuzumab trastuzumab and rHuPH20 injection for SC use) versus placebo plus Phesgo as maintenance therapy after first line induction therapy in Patients with untreated HER2 Positive PIK3CA Mutated Locally Advanced or Metastatic Breast Cancer
2022-502046-28-00 — injections, safety, breast neoplasms, neoplasms, maintenance, breast, therapeutics, trastuzumab		Phase 3Active not recruiting2023
A Study to Learn About the Study Medicine Called PF 07220060 in Combination With Letrozole in People Over 18 Years of Age With HR Positive HER2 Negative Advanced Metastatic Breast Cancer who Have not Received any Prior Systemic Anticancer Treatment for Advanced Metastatic Disease (FourLight 3)
2024-512925-95-00 — breast neoplasms, neoplasms, letrozole, hormones, breast, therapeutics		Phase 3Recruiting2025

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS